HEALTH● LOWAug 14 · Aug 14, 2026, 12:31 PM
Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’s
Seeking Alpha Tech
Lantheus has received approval from the FDA for its tau PET imaging agent, intended for use in Alzheimer's disease. This approval marks a significant development in medical diagnostics for Alzheimer's.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH16m agoKenya records second Ebola case as outbreak in Congo keeps growingEuroNews [en]HEALTH26m agoI work in the NHS and Malawi – we need to urgently rethink how we see health spendingThe Independent WorldHEALTH1h agoVaccines, antibiotics: Africa's push for pharma independence [Business Africa]Africanews [en]HEALTH1h agoNumber of people receiving weight loss jabs on NHS in Scotland revealedthenational.scot · United Kingdom